BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zelniker TA, Huscher D, Vonk-Noordegraaf A, Ewert R, Lange TJ, Klose H, Dumitrescu D, Halank M, Held M, Gall H, Pittrow D, Hoeper MM, Frankenstein L. The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. Clin Res Cardiol 2018;107:460-70. [PMID: 29368137 DOI: 10.1007/s00392-018-1207-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Toxvig AK, Wehland M, Grimm D, Infanger M, Krüger M. A focus on riociguat in the treatment of pulmonary arterial hypertension. Basic Clin Pharmacol Toxicol 2019;125:202-14. [PMID: 31206240 DOI: 10.1111/bcpt.13272] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
2 Costa GOS, Ramos RP, Oliveira RKF, Cepêda A, Vieira EB, Ivanaga IT, Ferreira EVM, Ota-Arakaki JS. Prognostic value of six-minute walk distance at a South American pulmonary hypertension referral center. Pulm Circ 2020;10:2045894019888422. [PMID: 32523683 DOI: 10.1177/2045894019888422] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Udi J, Köhler TC, Grohmann J, Bäuml M, Grundmann S, Bode C, Biever P, Duerschmied D. A challenging case of severe pulmonary bleeding in a patient with congenital ventricular septal defect (VSD) and Eisenmenger syndrome: extracorporeal membrane oxygenation (ECMO) support and weaning strategies. Clin Res Cardiol 2020;109:403-7. [PMID: 31501999 DOI: 10.1007/s00392-019-01544-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Thomas C, Glinskii V, de Jesus Perez V, Sahay S. Portopulmonary Hypertension: From Bench to Bedside. Front Med (Lausanne) 2020;7:569413. [PMID: 33224960 DOI: 10.3389/fmed.2020.569413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Coghlan JG, Picken C, Clapp LH. Selexipag in the management of pulmonary arterial hypertension: an update. Drug Healthc Patient Saf 2019;11:55-64. [PMID: 31496830 DOI: 10.2147/DHPS.S181313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Stadler S, Mergenthaler N, Lange TJ. The prognostic value of DLCO and pulmonary blood flow in patients with pulmonary hypertension. Pulm Circ 2019;9:2045894019894531. [PMID: 31908765 DOI: 10.1177/2045894019894531] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
7 Lachowska K, Bellwon J, Narkiewicz K, Gruchała M, Hering D. Long-term effects of device-guided slow breathing in stable heart failure patients with reduced ejection fraction. Clin Res Cardiol 2019;108:48-60. [PMID: 29943271 DOI: 10.1007/s00392-018-1310-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Lange TJ, Borst M, Ewert R, Halank M, Klose H, Leuchte H, Meyer FJ, Seyfarth HJ, Skowasch D, Wilkens H, Held M. [Current Aspects of Definition and Diagnosis of Pulmonary Hypertension]. Pneumologie 2020;74:847-63. [PMID: 32663892 DOI: 10.1055/a-1199-1548] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Wang ZR, Zhou JW, Liu XP, Cai GJ, Zhang QH, Mao JF. Effects of WeChat platform-based health management on health and self-management effectiveness of patients with severe chronic heart failure. World J Clin Cases 2021; 9(34): 10576-10584 [PMID: 35004989 DOI: 10.12998/wjcc.v9.i34.10576] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lachant DJ, Light AN, Mackin ML, Schwartz RG, White RJ. Heart Rate Expenditure Correlates with Right Ventricular Function. Ann Am Thorac Soc 2020;17:372-5. [PMID: 31682767 DOI: 10.1513/AnnalsATS.201909-683RL] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Mair KM, Gaw R, MacLean MR. Obesity, estrogens and adipose tissue dysfunction - implications for pulmonary arterial hypertension. Pulm Circ 2020;10:2045894020952019. [PMID: 32999709 DOI: 10.1177/2045894020952023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wronski SL, Mordin M, Kelley K, Anguiano RH, Classi P, Shen E, Manaker S. The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension. Lung 2020;198:65-86. [PMID: 31722043 DOI: 10.1007/s00408-019-00289-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]